At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 171 enrolled
Drug / intervention
INCB054707 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo
In Brief
A Phase 2 clinical trial evaluating INCB054707 and Placebo for NonSegmental Vitiligo. Completed, enrolled 171 participants across 31 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of INCB054707 over a 24-week placebo-controlled double-blind treatment period, followed by a 28-week double-blind extension period in participants with nonsegmental vitiligo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonSegmental Vitiligo
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartMay 2021
Primary CompletionMay 2022
Study CompletionMay 2023
TodayJul 2026
First PostedMar 26, 2021
Enrollment StartMay 6, 2021
Primary CompletionMay 24, 2022
Study CompletionMay 24, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.3 years ago
Interventions
INCB054707drug
INCB054707 will be administered once daily
Placebodrug
Placebo or INCB054707 will be administered once daily